Viridian Therapeutics Inc

VRDN.US
Healthcare · Biotechnology
19.51
-0.19 (-0.96%)
USD · NASDAQ

Company Information

Company Name
Viridian Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US92790C1045
CIK: 0001590750
CUSIP: 92790C104
Currency: USD
Full Time Employees: 252
Phone: 617 272 4600
Fiscal Year End: December
IPO Date: Jun 18, 2014
Description:

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Address:

221 Crescent Street, Waltham, MA, United States, 02453

People

Directors & Officers

Name Title Year Born
Mr. Stephen F. Mahoney J.D., MBA CEO, President & Director 1971
Mr. Seth Harmon Chief Financial Officer 1981
Mr. Thomas W. Beetham J.D., MBA Chief Operating Officer 1970
Ms. Jennifer Tousignant J.D. Chief Legal Officer & Corporate Secretary 1973
Dr. Radhika Tripuraneni M.D., M.P.H. Chief Medical Officer 1980
Dr. Eric N. Olson Ph.D. Co-Founder & Chairman of Scientific Advisory Board NA
Dr. Michael R. Bristow M.D., Ph.D. Co-Founder & Member of the Scientific Advisory Board 1945
Dr. Marvin H. Caruthers Ph.D. Co-Founder & Scientific Advisory Board Member 1940
Mr. Vahe Bedian Ph.D. Co-Founder & Scientific Advisor NA
Ms. Melissa Manno Chief Human Resources Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 31, 2025 Jennifer Tousignant N/A Sale 2.27K $31.16 $70.80K
Oct 23, 2025 Fairmount Funds Management Llc N/A Purchase 454.55K $22.00 $10.00M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 15.38M Mar 31, 2026 13.93% $0.02 6.92%
BlackRock Inc 7.83M Mar 31, 2026 7.09% $0.00 21.76%
Bellevue Group AG 6.73M Mar 31, 2026 6.09% $3.13 54.32%
Vanguard Group Inc 5.61M Dec 31, 2025 5.08% $0.00 29.55%
State Street Corp 4.67M Mar 31, 2026 4.23% $0.00 34.80%
Vanguard Capital Management, LLC 4.17M Mar 31, 2026 3.77% $0.00 0.00%
Fairmount Funds Management LLC 3.91M Mar 31, 2026 3.54% $5.53 0.00%
VR Adviser, LLC 3.88M Mar 31, 2026 3.52% $2.83 0.00%
T. Rowe Price Associates, Inc. 3.21M Mar 31, 2026 2.90% $0.01 -6.79%
Paradigm Biocapital Advisors LP 3.15M Mar 31, 2026 2.85% $1.26 118.20%
Wellington Management Company LLP 3.08M Mar 31, 2026 2.79% $0.01 56.16%
Kynam Capital Management, LP 2.34M Mar 31, 2026 2.12% $2.83 59.24%
Geode Capital Management, LLC 2.33M Mar 31, 2026 2.11% $0.00 17.12%
Citadel Advisors Llc 2.32M Mar 31, 2026 2.10% $0.01 241.07%
Balyasny Asset Management LLC 2.32M Mar 31, 2026 2.10% $0.06 359.64%
Novo A/S 2.00M Mar 31, 2026 1.81% $3.17 -15.97%
Baker Bros Advisors LP 1.97M Mar 31, 2026 1.79% $0.22 0.00%
TANG CAPITAL MANAGEMENT LLC 1.79M Mar 31, 2026 1.62% $1.78 0.00%
Fisher Asset Management, LLC 1.77M Mar 31, 2026 1.60% $0.01 -0.67%
Vanguard Portfolio Management, LLC 1.64M Mar 31, 2026 1.49% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 State Street® SPDR® S&P® Biotech ETF 3.91M 3.54% ▼ 2.17% Jun 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 3.34M 3.02% ▼ 0.31% Jun 30, 2026
3 iShares Russell 2000 ETF 2.36M 2.14% ▲ 0.60% Jun 30, 2026
4 Fidelity Advisor Biotechnology I 1.78M 1.61% ▲ 0.00% May 31, 2026
5 Fidelity Select Health Care 1.50M 1.36% ▼ 10.71% May 31, 2026
6 T. Rowe Price Health Sciences 1.45M 1.31% ▲ 368.35% Jun 30, 2026
7 Strategic Advisers Fidelity US TtlStk 1.39M 1.26% ▲ 17.28% May 31, 2026
8 T. Rowe Price New Horizons 1.35M 1.22% ▲ 29.04% Jun 30, 2026
9 US Small-Cap Growth II Equity Comp 1.35M 1.22% ▲ 28.98% Jun 30, 2026
10 Fidelity Select Biotechnology 1.31M 1.18% ▲ 30.67% May 31, 2026

Financial Highlights

Market Cap: $2.18B
EBITDA: $-385.23M
Book Value: $4.92
Earnings/Share: $-3.43
Profit Margin: 0.00%
Operating Margin: -82,389.36%
ROA (TTM): -33.25%
ROE (TTM): -58.14%
Revenue (TTM): $70.92M
Revenue/Share (TTM): $0.79
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 95.80%

Valuation Metrics

Enterprise Value: $1.55B
Trailing P/E: 0.00
Forward P/E: 1.01

Shares Statistics

Shares Outstanding: 110.43M
Shares Float: 97.76M
% Insiders: 13.70%
% Institutions: 11,192.60%
Short % Float: 17.78%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$70.85M
Cost of Goods Sold
adjust
$-1.16M
Gross Profit
subtotal
$70.85M
SG&A
adjust
$-95.32M
R&D
adjust
$-338.93M
Operating Income
subtotal
$-363.40M
Other / Non-Operating Items
adjust
$20.79M
Net Income
subtotal
$-342.60M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VRDN.US!